References
- International Diabetes Federation Diabetes Atlas 8th Edition, Brussels, Belgium. Available from: http://www.diabetesatlas.org/ [last accessed 29 Sep 2019].
- Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–564.
- Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227–1239.
- Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16.
- Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015;122:1375–1394.
- Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–625.
- Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 2016;123:2376–2385.
- Stewart S, Yeong JL, Virgili G, et al. Pragmatism of randomized clinical trials on ranibizumab for the treatment of diabetic macular edema: impact on clinical outcomes. Retina 2020;40:919–927.
- Chiang CC, Chen WL, Lin JM, Tsai YY. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 2008;146:688–691.
- Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–563.
- Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514–2522.
- Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993–997.
- Chalam KV, Agarwal S, Brar VS, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea 2009;28:328–333.
- Liarakos VS, Papaconstantinou D, Vergados I, et al. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model. Eur J Ophthalmol 2014;24:299–308.
- Bayar SA, Altinors DD, Kucukerdonmez C, Akova YA. Severe corneal changes following intravitreal injection of bevacizumab. Ocul Immunol Inflamm 2010;18:268–274.
- Guzel H, Bakbak B, Koylu MT, et al. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutan Ocul Toxicol 2017;36:5–8.
- Papadakou P, Chatziralli I, Papathanassiou M, et al. The effect of diabetes mellitus on corneal endothelial cells and central corneal thickness: a case-control study. Ophthalmic Res 2020;63:550–554.
- Shin JP, Lee JW, Sohn BJ, et al. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation. J Glaucoma 2009;18:589–594.
- Kim TI, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009;50:4653–4659.
- Muto T, Machida S. Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study. Clin Ophthalmol 2019;13:373–381.
- Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 2010;29:849–852.
- Arslan GD, Guven D, Alkan AA, et al. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure. Cutan Ocul Toxicol 2019;38:344–348.
- Urban B, Szwabowicz M, Bakunowicz-Łazarczyk A. Effect of repeated intravitreal ranibizumab and aflibercept injections on the cornea in patients with age-related macular degeneration. J Ophthalmol 2020;2020:4928905.